The Efficacy and Safety of Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients: A Single-armed, Phase II Trial
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Tucidinostat (Primary) ; Zimberelimab (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Dec 2022 New trial record